scPharmaceuticals
SCPH
SCPH was delisted on the 6th of October, 2025.
38 hedge funds and large institutions have $103M invested in scPharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 7 closing their positions.
214% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 7
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
65% more funds holding
Funds holding: 23 → 38 (+15)
9% more capital invested
Capital invested by funds: $94.4M → $103M (+$8.79M)
0.66% more ownership
Funds ownership: 44.22% → 44.88% (+0.66%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$3.86M |
| 2 |
State Street
Boston,
Massachusetts
|
+$1.16M |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$934K |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$651K |
| 5 |
AIC
AWM Investment Company
New York
|
+$648K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$1.5M |
| 2 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
-$1.29M |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$568K |
| 4 |
Millennium Management
New York
|
-$462K |
| 5 |
Goldman Sachs
New York
|
-$308K |
SCPH Hedge Fund Activity: Q1 2018 in Review
38 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in scPharmaceuticals (SCPH) for Q1 2018, worth a combined $103M — up 9.3% from $94.4M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new SCPH positions and 7 closed out — a net gain of 15 holders — while 8 added to existing stakes and 4 trimmed.
The largest buyer was BlackRock, adding an estimated $3.86M. The largest seller was Nicholas Investment Partners, exiting entirely with an estimated $1.5M sold.
- 38 institutional investors held scPharmaceuticals (SCPH) as of Q1 2018, up from 23 in Q4 2017.
- Funds reported $103M of scPharmaceuticals stock for Q1 2018, up 9.3% quarter-over-quarter.
- 22 funds opened new scPharmaceuticals positions in Q1 2018 and 7 closed out, a net change of +15 holders.
- The largest scPharmaceuticals buyer in Q1 2018 was BlackRock, an estimated $3.86M added.
- The largest scPharmaceuticals seller in Q1 2018 was Nicholas Investment Partners, an estimated $1.5M sold.
Based on aggregated 13F filings for Q1 2018.